Theralase Technologies Inc. (CVE:TLT) on Friday said its photodynamic therapy (PDT) technology has been found to have the ability to increase survival by 925% in a very aggressive form of brain cancer, known as glioblastoma multiforme (GBM).
In an orthotopic rat model (GBM established in brain tissue), Theralase was able to demonstrate that the animal treated by the laser-activated Theralase PDC Rutherrin (TLD-1433 plus transferrin) technology survived for a total of 41 days post-treatment resulting in a 925% survival increase. The current survival rate for untreated animals is approximately four days.
The current median survival in humans without treatment is approximately 8.1 months or 0.7 year.
The current median survival in humans with extensive treatment (maximal surgical resection, radiotherapy, and concomitant and adjuvant chemotherapy with temozolomide) is approximately 14.1 months or 1.2 years.
GBM, also known as glioblastoma and Grade IV astrocytoma (malignant brain tumour made up of star-shaped cells), is the most common and most aggressive cancer that begins within the brain. GBM kills over 85 per cent of those diagnosed within five years.
The National Cancer Institute (NCI) estimates that in the United States, 22,850 adults (12,630 men and 10,280 women) were diagnosed with brain and other nervous system cancer in 2015. It also estimates that in 2015, 15,320 of these diagnoses resulted in death (67-per-cent mortality rate).
NCI estimates that GBM accounts for 52 per cent of all primary brain tumours and occurs primarily in adults between the ages of 45 and 70.
The PDT treatment methodology has not been optimized and was completed only on one animal suggesting that further optimizations with additional animals may significantly increase the efficacy of this treatment.
“The data obtained from this established orthotopic brain cancer model is extremely encouraging. My team and I look forward to optimising the Theralase PDT technology in this application over the next six months, to allow us sufficient data to design a phase Ib human clinical study for patients inflicted with GBM,” said Dr. Arkady Mandel, MD, PhD, DSc, chief scientific officer at Theralase.
Story by ProactiveInvestors